BAL-0891

N/A

Report date: 2022/03/14 10:16:20
NME

Base Information

Drug NameBAL-0891
Drug Alias NameBAL-0891
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity protein kinase TTK inhibitorsPolo like kinase 1 inhibitors
TargetsDual specificity protein kinase TTKPolo like kinase 1
Therapy Area/IndicationsSolid tumoursStomach NeoplasmsTriple Negative Breast Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerlandSouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBasilea Pharmaceutica Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBasilea Pharmaceutica LtdSillajen Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursStomach NeoplasmsTriple Negative Breast Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A